Payment overview · 2025
General Payments
$202.57
10 reported records · 8 companies
Healthcare provider profile · identity verified
Amanda Nicole Beard, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · WHEAT RIDGE, CO · NPI 1316558406
Verified facts
What the public records show
CMS Open Payments records show Amanda Nicole Beard, NP received $202.57 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.35 | 19.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.62 | 17.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.68 | 12.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $24.02 | 11.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.46 | 10.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.07 | 9.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.02 | 9.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.35 | 8.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $202.57 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 228 | 69 |
| Lisinopril | Lisinopril | 168 | 51 |
| Gabapentin | Gabapentin | 161 | 44 |
| Tramadol Hcl | Tramadol Hcl | 146 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 134 | 19 |
| Losartan Potassium | Losartan Potassium | 117 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 35 |
| Metformin Hcl | Metformin Hcl | 110 | 32 |
| Trazodone Hcl | Trazodone Hcl | 105 | 29 |
| Omeprazole | Omeprazole | 103 | 24 |
| Furosemide | Furosemide | 102 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 20 |
| Famotidine | Famotidine | 92 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 81 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 31 |
| Potassium Chloride | Potassium Chloride | 71 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 12 |
| Pregabalin | Pregabalin | 57 | 12 |
| Allopurinol | Allopurinol | 56 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 21 |
| Sertraline Hcl | Sertraline Hcl | 53 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 14 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 17 |
| Simvastatin | Simvastatin | 48 | 18 |
| Eliquis | Apixaban | 47 | 12 |
| Montelukast Sodium | Montelukast Sodium | 47 | suppressed |
| Methocarbamol | Methocarbamol | 46 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Belsomra | Suvorexant | 34 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 13 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Prednisone | Prednisone | 21 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Xtampza Er | Oxycodone Myristate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $202.57 · 10 records | PFIZER INC. | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, NEXIUM, OTEZLA, PREVNAR 20, REPATHA, REXULTI, SPRAVATO, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error